Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Gilead Sciences Inc
WARNING LETTER
•Gilead Sciences Inc•February 12, 2010

Gilead Sciences Inc – FDA Warning Letter, Feb 12, 2010

Record Details

The FDA issued a Warning Letter to Gilead Sciences, Inc. following a January 25 to February 12, 2010 inspection of their San Dimas, CA pharmaceutical manufacturing facility. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations for Finished Pharmaceuticals (21 CFR Parts 210 and 211), rendering their drug products adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act. The firm's March 2, 2010 response was deemed inadequate.

Key violations included failure to maintain adequate separate areas for aseptic processing to prevent contamination (21 CFR 211.42(c)(10)), such as an inadequately constructed aseptic processing room and an insufficient environmental monitoring program. The firm also failed to follow appropriate written procedures to prevent microbiological contamination of sterile drug products (21 CFR 211.113(b)), with personnel observed making excessive movements and not using proper sterile equipment containers. Additionally, Gilead lacked adequate written procedures for production and process controls (21 CFR 211.100(a)), leading to an unvalidated process re-validation. Investigations into batch failures to meet specifications were inadequate (21 CFR 211.192), with defective tablets being culled instead of thoroughly investigated. Finally, equipment was not cleaned and maintained at appropriate intervals (21 CFR 211.67(a)), lacking rationale for cleaning frequencies.

The FDA noted concerns about the Quality Unit's inadequate responsibilities and authority, citing reliance on sorting defective tablets. Gilead must promptly correct these violations, provide a written response within fifteen working days detailing corrective actions, recurrence prevention, and supporting documentation. Failure to comply may result in legal action, impact federal contracts, and hinder drug application approvals.

Company
Gilead Sciences Inc
Inspection date
February 12, 2010
Product type
Drugs
Office
Los Angeles District Office
People
  • Alonza E. Cruse (Director)
  • Ingeborg Small
View Company Profile

ID · 469c26d4-d9d9-468b-a8ac-af9a4f888f6b

Violation Codes9
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.42(c)(10)21 CFR 211.67(a)21 CFR 211.100(a)21 CFR 211.113(b)21 CFR 211.192FD&C Act 501(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Gilead Sciences Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.